Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 218

1.

GVHD: biology matters.

Ferrara JLM, Chaudhry MS.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):221-227. doi: 10.1182/asheducation-2018.1.221. Review.

PMID:
30504314
2.

GVHD: biology matters.

Ferrara JLM, Chaudhry MS.

Blood Adv. 2018 Nov 27;2(22):3411-3417. doi: 10.1182/bloodadvances.2018020214. Review.

3.

Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease.

Groth C, van Groningen LFJ, Matos TR, Bremmers ME, Preijers FWMB, Dolstra H, Reicherts C, Schaap NPM, van Hooren EHG, IntHout J, Masereeuw R, Netea MG, Levine JE, Morales G, Ferrara JL, Blijlevens NMA, van Oosterhout YVJM, Stelljes M, van der Velden WJFM.

Biol Blood Marrow Transplant. 2019 Apr;25(4):712-719. doi: 10.1016/j.bbmt.2018.10.020. Epub 2018 Nov 3.

PMID:
30399420
4.

Microbial metabolite sensor GPR43 controls severity of experimental GVHD.

Fujiwara H, Docampo MD, Riwes M, Peltier D, Toubai T, Henig I, Wu SJ, Kim S, Taylor A, Brabbs S, Liu C, Zajac C, Oravecz-Wilson K, Sun Y, Núñez G, Levine JE, van den Brink MRM, Ferrara JLM, Reddy P.

Nat Commun. 2018 Sep 10;9(1):3674. doi: 10.1038/s41467-018-06048-w.

5.

An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.

Hartwell MJ, Özbek U, Holler E, Renteria AS, Major-Monfried H, Reddy P, Aziz M, Hogan WJ, Ayuk F, Efebera YA, Hexner EO, Bunworasate U, Qayed M, Ordemann R, Wölfl M, Mielke S, Pawarode A, Chen YB, Devine S, Harris AC, Jagasia M, Kitko CL, Litzow MR, Kröger N, Locatelli F, Morales G, Nakamura R, Reshef R, Rösler W, Weber D, Wudhikarn K, Yanik GA, Levine JE, Ferrara JL.

JCI Insight. 2018 Aug 23;3(16). pii: 124015. doi: 10.1172/jci.insight.124015. eCollection 2018 Aug 23. No abstract available.

6.

Survival signal REG3α prevents crypt apoptosis to control acute gastrointestinal graft-versus-host disease.

Zhao D, Kim YH, Jeong S, Greenson JK, Chaudhry MS, Hoepting M, Anderson ER, van den Brink MR, Peled JU, Gomes AL, Slingerland AE, Donovan MJ, Harris AC, Levine JE, Ozbek U, Hooper LV, Stappenbeck TS, Ver Heul A, Liu TC, Reddy P, Ferrara JL.

J Clin Invest. 2018 Nov 1;128(11):4970-4979. doi: 10.1172/JCI99261. Epub 2018 Sep 24.

7.

Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802.

Holtan SG, DeFor TE, Panoskaltsis-Mortari A, Khera N, Levine JE, Flowers MED, Lee SJ, Inamoto Y, Chen GL, Mayer S, Arora M, Palmer J, Cutler CS, Arai S, Lazaryan A, Newell LF, Jagasia MH, Pusic I, Wood WA, Renteria AS, Yanik G, Hogan WJ, Hexner E, Ayuk F, Holler E, Bunworasate U, Efebera YA, Ferrara JLM, Pidala J, Howard A, Wu J, Bolaños-Meade J, Ho V, Alousi A, Blazar BR, Weisdorf DJ, MacMillan ML.

Blood Adv. 2018 Aug 14;2(15):1882-1888. doi: 10.1182/bloodadvances.2018017343.

8.

EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment.

Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, Shaw BE, Flowers ME, Ruutu T, Greinix H, Holler E, Basak G, Duarte RF, Pavletic SZ; EBMT (European Society for Blood and Marrow Transplantation) Transplant Complications Working Party and the “EBMT−NIH (National Institutes of Health)−CIBMTR (Center for International Blood and Marrow Transplant Research) GvHD Task Force”.

Bone Marrow Transplant. 2018 Nov;53(11):1401-1415. doi: 10.1038/s41409-018-0204-7. Epub 2018 Jun 5.

PMID:
29872128
9.

MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD.

Major-Monfried H, Renteria AS, Pawarode A, Reddy P, Ayuk F, Holler E, Efebera YA, Hogan WJ, Wölfl M, Qayed M, Hexner EO, Wudhikarn K, Ordemann R, Young R, Shah J, Hartwell MJ, Chaudhry MS, Aziz M, Etra A, Yanik GA, Kröger N, Weber D, Chen YB, Nakamura R, Rösler W, Kitko CL, Harris AC, Pulsipher M, Reshef R, Kowalyk S, Morales G, Torres I, Özbek U, Ferrara JLM, Levine JE.

Blood. 2018 Jun 21;131(25):2846-2855. doi: 10.1182/blood-2018-01-822957. Epub 2018 Mar 15.

PMID:
29545329
10.

In vivo IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation.

Pidala J, Beato F, Kim J, Betts B, Jim H, Sagatys E, Levine JE, Ferrara JLM, Ozbek U, Ayala E, Davila M, Fernandez HF, Field T, Kharfan-Dabaja MA, Khaira D, Khimani F, Locke FL, Mishra A, Nieder M, Nishihori T, Perez L, Riches M, Anasetti C.

Haematologica. 2018 Mar;103(3):531-539. doi: 10.3324/haematol.2017.171199. Epub 2017 Dec 14.

11.

T Cell-Mediated Rejection of Human CD34+ Cells Is Prevented by Costimulatory Blockade in a Xenograft Model.

Oh AL, Mahmud D, Nicolini B, Mahmud N, Senyuk V, Patel PR, Bonetti E, Arpinati M, Ferrara JLM, Rondelli D.

Biol Blood Marrow Transplant. 2017 Dec;23(12):2048-2056. doi: 10.1016/j.bbmt.2017.08.009. Epub 2017 Aug 14.

12.

Altered homeostatic regulation of innate and adaptive immunity in lower gastrointestinal tract GVHD pathogenesis.

Ferrara JL, Smith CM, Sheets J, Reddy P, Serody JS.

J Clin Invest. 2017 Jun 30;127(7):2441-2451. doi: 10.1172/JCI90592. Epub 2017 Jun 5. Review.

13.

An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.

Hartwell MJ, Özbek U, Holler E, Renteria AS, Major-Monfried H, Reddy P, Aziz M, Hogan WJ, Ayuk F, Efebera YA, Hexner EO, Bunworasate U, Qayed M, Ordemann R, Wölfl M, Mielke S, Pawarode A, Chen YB, Devine S, Harris AC, Jagasia M, Kitko CL, Litzow MR, Kröger N, Locatelli F, Morales G, Nakamura R, Reshef R, Rösler W, Weber D, Wudhikarn K, Yanik GA, Levine JE, Ferrara JL.

JCI Insight. 2017 Feb 9;2(3):e89798. doi: 10.1172/jci.insight.89798. Erratum in: JCI Insight. 2018 Aug 23;3(16):.

14.

Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors.

Holtan SG, Khera N, Levine JE, Chai X, Storer B, Liu HD, Inamoto Y, Chen GL, Mayer S, Arora M, Palmer J, Flowers MED, Cutler CS, Lukez A, Arai S, Lazaryan A, Newell LF, Krupski C, Jagasia MH, Pusic I, Wood W, Renteria AS, Yanik G, Hogan WJ, Hexner E, Ayuk F, Holler E, Watanaboonyongcharoen P, Efebera YA, Ferrara JLM, Panoskaltsis-Mortari A, Weisdorf D, Lee SJ, Pidala J.

Blood. 2016 Nov 10;128(19):2350-2358. doi: 10.1182/blood-2015-09-669846. Epub 2016 Sep 13.

15.

Development of a biomarker scoring system for use in graft-versus-host disease.

Renteria AS, Levine JE, Ferrara JL.

Biomark Med. 2016 Aug;10(8):793-5. doi: 10.2217/bmm-2016-0162. Epub 2016 Jul 14. No abstract available.

16.

Therapeutic targets and emerging treatment options in gastrointestinal acute graft-versus-host disease.

Renteria AS, Levine JE, Ferrara JLM.

Expert Opin Orphan Drugs. 2016;4(5):469-484. doi: 10.1517/21678707.2016.1166949. Epub 2016 Apr 6.

17.

A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.

Levine JE, Braun TM, Harris AC, Holler E, Taylor A, Miller H, Magenau J, Weisdorf DJ, Ho VT, Bolaños-Meade J, Alousi AM, Ferrara JL; Blood and Marrow Transplant Clinical Trials Network.

Lancet Haematol. 2015 Jan;2(1):e21-9. doi: 10.1016/S2352-3026(14)00035-0. Epub 2014 Dec 23.

18.

Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial.

Kitko CL, Braun T, Couriel DR, Choi SW, Connelly J, Hoffmann S, Goldstein S, Magenau J, Pawarode A, Reddy P, Schuler C, Yanik GA, Ferrara JL, Levine JE.

Biol Blood Marrow Transplant. 2016 May;22(5):862-8. doi: 10.1016/j.bbmt.2015.11.002. Epub 2015 Nov 6.

19.

International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium.

Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, Chanswangphuwana C, Efebera YA, Holler E, Litzow M, Ordemann R, Qayed M, Renteria AS, Reshef R, Wölfl M, Chen YB, Goldstein S, Jagasia M, Locatelli F, Mielke S, Porter D, Schechter T, Shekhovtsova Z, Ferrara JL, Levine JE.

Biol Blood Marrow Transplant. 2016 Jan;22(1):4-10. doi: 10.1016/j.bbmt.2015.09.001. Epub 2015 Sep 16.

20.

Rethinking the paradigm: How comparative studies on fatty acid oxidation inform our understanding of T cell metabolism.

Chiaranunt P, Ferrara JL, Byersdorfer CA.

Mol Immunol. 2015 Dec;68(2 Pt C):564-74. doi: 10.1016/j.molimm.2015.07.023. Epub 2015 Sep 8. Review.

PMID:
26359186
21.

Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series.

Pawarode A, Mineishi S, Reddy P, Braun TM, Khaled YA, Choi SW, Magenau JM, Harris AC, Connelly JA, Kitko CL, Parkin BL, Goldstein SC, Yanik GA, Levine JE, Ferrara JL, Couriel DR.

Biol Blood Marrow Transplant. 2016 Jan;22(1):54-60. doi: 10.1016/j.bbmt.2015.07.021. Epub 2015 Jul 26.

22.

Programmed death-1 controls T cell survival by regulating oxidative metabolism.

Tkachev V, Goodell S, Opipari AW, Hao LY, Franchi L, Glick GD, Ferrara JL, Byersdorfer CA.

J Immunol. 2015 Jun 15;194(12):5789-800. doi: 10.4049/jimmunol.1402180. Epub 2015 May 13.

23.

The IL-33/ST2 axis augments effector T-cell responses during acute GVHD.

Reichenbach DK, Schwarze V, Matta BM, Tkachev V, Lieberknecht E, Liu Q, Koehn BH, Pfeifer D, Taylor PA, Prinz G, Dierbach H, Stickel N, Beck Y, Warncke M, Junt T, Schmitt-Graeff A, Nakae S, Follo M, Wertheimer T, Schwab L, Devlin J, Watkins SC, Duyster J, Ferrara JL, Turnquist HR, Zeiser R, Blazar BR.

Blood. 2015 May 14;125(20):3183-92. doi: 10.1182/blood-2014-10-606830. Epub 2015 Mar 26.

24.

A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.

MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A, Ho VT, Bolaños-Meade J, Ferrara JL, Jones R, Arora M, Blazar BR, Holtan SG, Jacobsohn D, Pasquini M, Socie G, Antin JH, Levine JE, Weisdorf DJ.

Biol Blood Marrow Transplant. 2015 Apr;21(4):761-7. doi: 10.1016/j.bbmt.2015.01.001. Epub 2015 Jan 10.

25.

Improved accuracy of acute graft-versus-host disease staging among multiple centers.

Levine JE, Hogan WJ, Harris AC, Litzow MR, Efebera YA, Devine SM, Reshef R, Ferrara JL.

Best Pract Res Clin Haematol. 2014 Sep-Dec;27(3-4):283-7. doi: 10.1016/j.beha.2014.10.011. Epub 2014 Oct 15. Review.

26.

Anaplerotic metabolism of alloreactive T cells provides a metabolic approach to treat graft-versus-host disease.

Glick GD, Rossignol R, Lyssiotis CA, Wahl D, Lesch C, Sanchez B, Liu X, Hao LY, Taylor C, Hurd A, Ferrara JL, Tkachev V, Byersdorfer CA, Boros L, Opipari AW.

J Pharmacol Exp Ther. 2014 Nov;351(2):298-307. doi: 10.1124/jpet.114.218099. Epub 2014 Aug 14.

27.

Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.

Gatza E, Braun T, Levine JE, Ferrara JL, Zhao S, Wang T, Chang L, Harris A, Pawarode A, Kitko C, Magenau JM, Yanik GA, Couriel DR, Goldstein S, Connelly J, Reddy P, Paczesny S, Choi SW.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1426-34. doi: 10.1016/j.bbmt.2014.05.023. Epub 2014 Jun 2.

28.

Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes.

Chang L, Frame D, Braun T, Gatza E, Hanauer DA, Zhao S, Magenau JM, Schultz K, Tokala H, Ferrara JL, Levine JE, Reddy P, Paczesny S, Choi SW.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1407-17. doi: 10.1016/j.bbmt.2014.05.022. Epub 2014 Jun 2.

29.

Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocol.

Yanik GA, Horowitz MM, Weisdorf DJ, Logan BR, Ho VT, Soiffer RJ, Carter SL, Wu J, Wingard JR, Difronzo NL, Ferrara JL, Giralt S, Madtes DK, Drexler R, White ES, Cooke KR.

Biol Blood Marrow Transplant. 2014 Jun;20(6):858-64. doi: 10.1016/j.bbmt.2014.02.026. Epub 2014 Mar 7.

30.

Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease.

Holler E, Butzhammer P, Schmid K, Hundsrucker C, Koestler J, Peter K, Zhu W, Sporrer D, Hehlgans T, Kreutz M, Holler B, Wolff D, Edinger M, Andreesen R, Levine JE, Ferrara JL, Gessner A, Spang R, Oefner PJ.

Biol Blood Marrow Transplant. 2014 May;20(5):640-5. doi: 10.1016/j.bbmt.2014.01.030. Epub 2014 Jan 31.

31.

Plasma CXCL9 elevations correlate with chronic GVHD diagnosis.

Kitko CL, Levine JE, Storer BE, Chai X, Fox DA, Braun TM, Couriel DR, Martin PJ, Flowers ME, Hansen JA, Chang L, Conlon M, Fiema BJ, Morgan R, Pongtornpipat P, Lamiman K, Ferrara JL, Lee SJ, Paczesny S.

Blood. 2014 Jan 30;123(5):786-93. doi: 10.1182/blood-2013-08-520072. Epub 2013 Dec 20.

32.

Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial.

Choi SW, Braun T, Chang L, Ferrara JL, Pawarode A, Magenau JM, Hou G, Beumer JH, Levine JE, Goldstein S, Couriel DR, Stockerl-Goldstein K, Krijanovski OI, Kitko C, Yanik GA, Lehmann MH, Tawara I, Sun Y, Paczesny S, Mapara MY, Dinarello CA, DiPersio JF, Reddy P.

Lancet Oncol. 2014 Jan;15(1):87-95. doi: 10.1016/S1470-2045(13)70512-6. Epub 2013 Nov 30.

33.

Blood and Marrow Transplant Clinical Trials Network: progress since the State of the Science Symposium 2007.

Ferrara JL.

Biol Blood Marrow Transplant. 2014 Feb;20(2):149-53. doi: 10.1016/j.bbmt.2013.11.006. Epub 2013 Nov 12.

34.

Effector T cells require fatty acid metabolism during murine graft-versus-host disease.

Byersdorfer CA, Tkachev V, Opipari AW, Goodell S, Swanson J, Sandquist S, Glick GD, Ferrara JL.

Blood. 2013 Oct 31;122(18):3230-7. doi: 10.1182/blood-2013-04-495515. Epub 2013 Sep 17.

35.

ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.

Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, Zhang Q, Wong CH, Wang H, Chin A, Gomez A, Harris AC, Levine JE, Choi SW, Couriel D, Reddy P, Ferrara JL, Paczesny S.

N Engl J Med. 2013 Aug 8;369(6):529-39. doi: 10.1056/NEJMoa1213299.

36.

Low Paneth cell numbers at onset of gastrointestinal graft-versus-host disease identify patients at high risk for nonrelapse mortality.

Levine JE, Huber E, Hammer ST, Harris AC, Greenson JK, Braun TM, Ferrara JL, Holler E.

Blood. 2013 Aug 22;122(8):1505-9. doi: 10.1182/blood-2013-02-485813. Epub 2013 Jun 12.

37.

Advances in predicting acute GVHD.

Harris AC, Ferrara JL, Levine JE.

Br J Haematol. 2013 Feb;160(3):288-302. doi: 10.1111/bjh.12142. Epub 2012 Dec 4. Review.

38.

Have we made progress in the treatment of GVHD?

Harris AC, Levine JE, Ferrara JL.

Best Pract Res Clin Haematol. 2012 Dec;25(4):473-8. doi: 10.1016/j.beha.2012.10.010. Epub 2012 Oct 25. Review.

39.

Distinct metabolic programs in activated T cells: opportunities for selective immunomodulation.

Wahl DR, Byersdorfer CA, Ferrara JL, Opipari AW Jr, Glick GD.

Immunol Rev. 2012 Sep;249(1):104-15. doi: 10.1111/j.1600-065X.2012.01148.x. Review.

40.

TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes.

Choi SW, Stiff P, Cooke K, Ferrara JL, Braun T, Kitko C, Reddy P, Yanik G, Mineishi S, Paczesny S, Hanauer D, Pawarode A, Peres E, Rodriguez T, Smith S, Levine JE.

Biol Blood Marrow Transplant. 2012 Oct;18(10):1525-32. doi: 10.1016/j.bbmt.2012.03.013. Epub 2012 Mar 30.

41.

Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study.

Levine JE, Logan BR, Wu J, Alousi AM, Bolaños-Meade J, Ferrara JL, Ho VT, Weisdorf DJ, Paczesny S.

Blood. 2012 Apr 19;119(16):3854-60. doi: 10.1182/blood-2012-01-403063. Epub 2012 Mar 1.

42.

Plasma biomarkers of lower gastrointestinal and liver acute GVHD.

Harris AC, Ferrara JL, Braun TM, Holler E, Teshima T, Levine JE, Choi SW, Landfried K, Akashi K, Vander Lugt M, Couriel DR, Reddy P, Paczesny S.

Blood. 2012 Mar 22;119(12):2960-3. doi: 10.1182/blood-2011-10-387357. Epub 2012 Jan 27.

43.

Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease.

Ferrara JL, Harris AC, Greenson JK, Braun TM, Holler E, Teshima T, Levine JE, Choi SW, Huber E, Landfried K, Akashi K, Vander Lugt M, Reddy P, Chin A, Zhang Q, Hanash S, Paczesny S.

Blood. 2011 Dec 15;118(25):6702-8. doi: 10.1182/blood-2011-08-375006. Epub 2011 Oct 6.

44.

Manipulating the bioenergetics of alloreactive T cells causes their selective apoptosis and arrests graft-versus-host disease.

Gatza E, Wahl DR, Opipari AW, Sundberg TB, Reddy P, Liu C, Glick GD, Ferrara JL.

Sci Transl Med. 2011 Jan 26;3(67):67ra8. doi: 10.1126/scitranslmed.3001975.

45.

Mouse models of graft-versus-host disease.

Reddy P, Ferrara JLM.

StemBook [Internet]. Cambridge (MA): Harvard Stem Cell Institute; 2008-.
2009 Feb 28.

46.

Elafin is a biomarker of graft-versus-host disease of the skin.

Paczesny S, Braun TM, Levine JE, Hogan J, Crawford J, Coffing B, Olsen S, Choi SW, Wang H, Faca V, Pitteri S, Zhang Q, Chin A, Kitko C, Mineishi S, Yanik G, Peres E, Hanauer D, Wang Y, Reddy P, Hanash S, Ferrara JL.

Sci Transl Med. 2010 Jan 6;2(13):13ra2. doi: 10.1126/scitranslmed.3000406.

47.

Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease.

Magenau JM, Qin X, Tawara I, Rogers CE, Kitko C, Schlough M, Bickley D, Braun TM, Jang PS, Lowler KP, Jones DM, Choi SW, Reddy P, Mineishi S, Levine JE, Ferrara JL, Paczesny S.

Biol Blood Marrow Transplant. 2010 Jul;16(7):907-14. doi: 10.1016/j.bbmt.2010.02.026. Epub 2010 Mar 17.

48.

Identification of stem cell transcriptional programs normally expressed in embryonic and neural stem cells in alloreactive CD8+ T cells mediating graft-versus-host disease.

Kato K, Cui S, Kuick R, Mineishi S, Hexner E, Ferrara JL, Emerson SG, Zhang Y.

Biol Blood Marrow Transplant. 2010 Jun;16(6):751-71. doi: 10.1016/j.bbmt.2010.01.012. Epub 2010 Jan 29.

49.

Pathogenesis and management of graft-versus-host disease.

Choi SW, Levine JE, Ferrara JL.

Immunol Allergy Clin North Am. 2010 Feb;30(1):75-101. doi: 10.1016/j.iac.2009.10.001. Review.

50.

Corticosteroid regimens for treatment of acute and chronic graft versus host disease (GvHD) after allogenic stem cell transplantation.

Salmasian H, Rohanizadegan M, Banihosseini S, Rahimi Darabad R, Rabbani-Anari M, Shakiba A, Ferrara JL.

Cochrane Database Syst Rev. 2010 Jan 20;(1):CD005565. doi: 10.1002/14651858.CD005565.pub2. Review.

PMID:
20091579

Supplemental Content

Loading ...
Support Center